Key terms
About VIRX
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VIRX news
Mar 20
4:52pm ET
Viracta Therapeutics CFO Resigns, Interim Successor Appointed
Mar 12
6:28am ET
Buy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financials
Mar 11
12:50am ET
Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
Mar 08
7:27am ET
RBC Capital Sticks to Its Buy Rating for Viracta Therapeutics (VIRX)
Mar 07
4:41pm ET
Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)
Feb 29
8:18am ET
Viracta announces completion of second-stage enrollment in NAVAL-1 trial
Feb 15
12:25pm ET
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
Feb 15
4:55am ET
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
Feb 13
5:12pm ET
Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
Jan 05
6:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 05
6:11am ET
Viracta Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
Jan 04
8:24am ET
Viracta Therapeutics provides anticipated 2024 milestones
No recent news articles are available for VIRX
No recent press releases are available for VIRX
VIRX Financials
Key terms
Ad Feedback
VIRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VIRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range